- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06716073
Résultats à long terme de la chirurgie conservatrice du sein assistée par endoscopie ou conventionnelle chez les patientes atteintes d'un cancer du sein après un traitement néoadjuvant : un essai randomisé, multicentrique, ouvert et de non-infériorité
With the title of "Long-Term Outcomes of endoscopic-assisted vs conventional breast-conserving surgery in breast cancer patients after neoadjuvant therapy: a randomized, multicenter, open label, non-inferiority trial", this study targets breast cancer patients after neoadjuvant therapy. A total of 804 eligible patients, after screening with inclusion and exclusion criteria, will be randomly assigned to Endoscopic-assisted breast conserving surgery(E-BCS) or conventional breast conserving surgery (C-BCS) group at a 1:1 ratio using stratified block randomization method, stratified by centers and molecular subtype. The co-primary endpoints are 5-year disease-free survival (5y-DFS) and Breast-Q score at 6 months after surgery. The secondary endpoints are cosmetic outcomes including surgeons' satisfaction with breast and patients' satisfaction with scar, survival outcomes including 5-year overall survival (5y-OS) and 5-year local-recurrence rate (5y-LRR), surgical outcomes including operative time, intraoperative blood loss, incision length and postoperative complications rate. This study aims to confirm the long-term safety and aesthetic outcome of endoscopic-assisted surgery in breast cancer patients after neoadjuvant treatment by comparing it with conventional open breast conserving surgery, and provide clinical evidence for the popularized application of endoscopic breast surgery.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Shicheng Su
- Numéro de téléphone: +86-13631304227
- E-mail: sushch@mail.sysu.edu.cn
Sauvegarde des contacts de l'étude
- Nom: Yiwen Lu, Doctor
- Numéro de téléphone: +86-13268121885
- E-mail: luyw8@mail.sysu.edu.cn
Lieux d'étude
-
-
Guangdong
-
Guangzhou, Guangdong, Chine, 510120
- Recrutement
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
-
Contact:
- Shicheng Su
- Numéro de téléphone: +86-13631304227
- E-mail: sushch@mail.sysu.edu.cn
-
Shantou, Guangdong, Chine
- Pas encore de recrutement
- Sun Yat-sen Memorial Hospital of Sun Yat-sen University Shenzhen Shantou Central Hospital
-
Contact:
- Yandan Yao
- Numéro de téléphone: +86-13826292688
- E-mail: yaoyand@mail.sysu.edu.cn
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age ranging from 18 to 75 years
- Pathologically confirmed invasive breast cancer
- Receiving preoperative chemotherapy (Each molecular subtype corresponds to unanimous regimen)
- cT1-3N0-3M0
- Unilateral breast tumor
- Eastern Cooperative Oncology Group score 0-1
- Left Ventricular Ejection Fraction (LVEF) ≥50%
- Leukocytes ≥ 3.0×109/L, Absolute neutrophil count ≥ 1.5×109/L, Platelets ≥ 100×109/L, Hemoglobin ≥ 90g/L, Creatinine <1.5 × institutional ULN, Total bilirubin ≤ 2.0 × institutional ULN.
Exclusion Criteria:
- Diffusely disseminated malignant calcification foci
- Not applicable for BCS after neoadjuvant therapy
- Pregnancy or breastfeeding
- Additional malignancy
- Severe cardiopulmonary, liver or kidney dysfunction or other systemic diseases (such as uncontrolled chronic heart failure, critical hypertension or diabetes with poor blood glucose control).
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Groupe de chirurgie endoscopique conservatrice du sein (E-BCS)
|
comparison of 2 surgical procedures |
|
Aucune intervention: Groupe chirurgie mammaire conservatrice conventionnelle (C-BCS)
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
5-year disease free survival
Délai: From surgery to the end of follow-up at 5 years
|
The proportion of patients remaining after excluding patients with disease recurrence, metastasis or death from the time of surgery to 5-year follow-up |
From surgery to the end of follow-up at 5 years
|
|
Patients' satisfaction with breast
Délai: From surgery to the follow-up at 6 months
|
The score of Breast-Q scale "Satisfaction with breasts" table 6 months after surgery |
From surgery to the follow-up at 6 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Surgeons' satisfaction with breast
Délai: From surgery to the follow-up at 6 months
|
Surgeons evaluate the cosmetic outcome of breast based on the photos before surgery and after surgery. Four ranks: Excellent (9-10 points), Good (7-8 points), Fair (5-6 points) and Poor (0-4 points) are categorized on a basis of average total score from Ueda scale |
From surgery to the follow-up at 6 months
|
|
Patients satisfaction with scar
Délai: From surgery to the follow-up at 6 months
|
Scar-Q scale including 3 tables about the surgical scar: appearance, symptom, psychosocial impact with total score of 100 will be used for evaluating patients satisfaction with scar |
From surgery to the follow-up at 6 months
|
|
5-year overall survival
Délai: From surgery to the end of follow-up at 5 years
|
The proportion of patients remaining after excluding patients who died from any cause at 5-year follow-up |
From surgery to the end of follow-up at 5 years
|
|
5-year local-regional recurrence rate
Délai: From surgery to the end of follow-up at 5 years
|
The proportion of patients with a lump found on breast, axilla, chest wall, skin or scars of surgery ipsilateral to the surgical side through physical examination or imaging, confirmed as the same pathological type as the primary tumor according to biopsy at 5-year follow up |
From surgery to the end of follow-up at 5 years
|
|
Postoperative complication rate
Délai: From surgery to the follow-up at 12 months
|
The proportion of patients with postoperative complications including hemorrhage, incision dehiscence, upper limb lymphedema, infection,seroma. |
From surgery to the follow-up at 12 months
|
|
Surgical duration
Délai: Intraoperative
|
The time from the beginning of surgery to the end of surgery |
Intraoperative
|
|
Intraoperative blood loss
Délai: Intraoperative
|
The blood loss during the operation |
Intraoperative
|
|
Incision length
Délai: Intraoperative
|
The length of surgical incision |
Intraoperative
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chaise d'étude: Shicheng Su, Doctor, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- SYSKY-2024-648-01
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .